文献速递中药与中成药合理使用中医内科

盐酸伊立替康注射液与康艾注射液在结直肠肿瘤小鼠及健康大鼠中的药理学与药代动力学相互作用评价

Evaluation of pharmacological and pharmacokinetic herb-drug interaction between irinotecan hydrochloride injection and Kangai injection in colorectal tumor-bearing mice and healthy rats.
PubMed 文献 · Front Pharmacol · 2023-11-29

该临床前研究在CT26结直肠肿瘤小鼠中评价康艾注射液与伊立替康联用的药效与毒性,并在健康SD大鼠中测定康艾6种成分的药代动力学。结果显示康艾可增强伊立替康抗结直肠癌疗效并减轻其所致体重下降;联用抑制氧化苦参碱代谢为苦参碱,苦参碱Cmax和AUC0-t显著降低(p<0.05)。

要点

  • 康艾注射液可能增强伊立替康抗结直肠癌疗效并减轻体重下降。
  • 联用后苦参碱Cmax由2.23±0.24降至1.38±0.12 μg/mL,AUC0-t由8.29±1.34降至5.30±0.79 μg h/mL。
  • 氧化苦参碱与苦参碱功效相似,该代谢抑制可能不影响抗癌效果。

核心结论

  • 康艾注射液与伊立替康联用具有增强抗结直肠癌疗效和减轻体重下降的临床前获益,同时存在抑制氧化苦参碱代谢为苦参碱的药代动力学风险。

研究设计与样本

  • 药理学研究将CT26结直肠肿瘤BALB/c小鼠分为4组,分别给予生理盐水、伊立替康100 mg/kg、康艾10 mL/kg及两者联用,每日监测肿瘤体积并分析体重、生存率、造血毒性、免疫器官指数和肠道毒性。
  • 药代动力学研究在健康SD大鼠中单用康艾4 mL/kg或联用伊立替康20 mg/kg与康艾,采用LC-MS/MS测定给药后24 h内血浆中氧化苦参碱、苦参碱、人参皂苷Rb1、Rg1、Re及黄芪甲苷IV。

主要发现

  • 药理学研究显示康艾注射液有增强伊立替康抗结直肠癌疗效的潜力,并缓解伊立替康所致严重体重下降。
  • 药代动力学研究显示联用抑制大鼠体内氧化苦参碱代谢,其代谢物苦参碱的Cmax由2.23±0.24降至1.38±0.12 μg/mL,AUC0-t由8.29±1.34降至5.30±0.79 μg h/mL(p<0.05)。
  • 因氧化苦参碱与苦参碱功效相似,该代谢抑制可能不损害该药对组合的抗癌效果。

关键数值与推荐

  • 小鼠给药剂量:伊立替康100 mg/kg,康艾10 mL/kg;大鼠给药剂量:康艾4 mL/kg,伊立替康20 mg/kg。
  • 苦参碱Cmax由2.23±0.24 μg/mL降至1.38±0.12 μg/mL,AUC0-t由8.29±1.34 μg h/mL降至5.30±0.79 μg h/mL,p<0.05。

临床怎么用

  • 该临床前结果为伊立替康与康艾注射液临床联用提供参考,提示联用可能增强疗效并减轻体重下降。
  • 联用可能抑制氧化苦参碱代谢,临床需关注该药对组合的药代动力学相互作用。

局限性

  • 原文未报告药理学与药代动力学研究的具体样本量。
  • 药代动力学研究在健康大鼠中进行,药理学研究在荷瘤小鼠中进行,种属与病理状态差异可能影响外推。
  • 研究为临床前研究,尚需临床研究验证联用的疗效与安全性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Introduction: Kangai (KA) injection, a Chinese herbal injection, is often used in combination with irinotecan (CPT-11) to enhance the effectiveness of anti-colorectal cancer treatment and alleviate side effects. However, the combined administration of this herb-drug pair remains controversial due to limited pre-clinical evidence and safety concerns. This study aimed to determine the pre-clinical herb-drug interactions between CPT-11 and KA injection to provide a reference for their clinical co-administration. Methods: In the pharmacological study, BALB/c mice with CT26 colorectal tumors were divided into four groups and treated with vehicle alone (0.9% saline), CPT-11 injection (100 mg/kg), KA injection (10 mL/kg), or a combination of CPT-11 and KA injection, respectively. The tumor volume of mice was monitored daily to evaluate the therapeutic effect. Daily body weight, survival rate, hematopoietic toxicity, immune organ indices, and gut toxicity were analyzed to study the adverse effects. Healthy Sprague-Dawley rats in the pharmacokinetic study were administered KA injection only (4 mL/kg), or a combination of CPT-11 injection (20 mg/kg) and KA injection, respectively. Six key components of KA injection (oxymatrine, matrine, ginsenoside Rb1, Rg1, Re, and astragaloside IV) in rat plasma samples collected within 24 h after administration were determined by LC-MS/MS. Results: The pharmacological study indicated that KA injection has the potential to enhance the anti-colorectal cancer efficacy of CPT-11 injection and alleviate the severe weight loss induced by CPT-11 injection in tumor-bearing mice. The pharmacokinetic study revealed that co-administration resulted in inhibition of oxymatrine metabolism in rats, evidenced by the significantly reduced Cmax and AUC0-t of its metabolite, matrine (p < 0.05), from 2.23 ± 0.24 to 1.38 ± 0.12 μg/mL and 8.29 ± 1.34 to 5.30 ± 0.79 μg h/mL, respectively. However, due to the similar efficacy of oxymatrine and matrine, this may not compromise the anti-cancer effect of this herb-drug pair. Discussion: This study clarified the pre-clinical pharmacology and pharmacokinetic benefits and risks of the CPT-11-KA combination and provided a reference for their clinical co-administration.

来源:Front Pharmacol,查看原文。版权归原作者所有。

引用

  1. Chen Y, Hu Z, Jiang J, et al. Evaluation of pharmacological and pharmacokinetic herb-drug interaction between irinotecan hydrochloride injection and Kangai injection in colorectal tumor-bearing mice and healthy rats. Front Pharmacol. 2023. PMID: 38094890. doi:10.3389/fphar.2023.1282062

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。